Press release
What makes a Biobetter is to be discussed at SMi’s Biosimilars and Biobetters conference
Join SMi at their 2nd Biosimilars and Biobetters conference where you can expect to learn about a comprehensive range of pivotal issues in this area, not just relating to the development of the US regulatory pathway and the early steps of the EMA, but also the scientific developmental agenda of major players in the fledgling industry, the unique and exciting position of mAbs in this new arena, how Biobetters and Biosuperiors could challenge second generation biologics, and analysis of global biosimilars pricings structure. Presented by leading industry figures and stakeholders, this event is an unmissable opportunity to gather vital information and contacts to work towards an optimal position in the biosimilars market.
Register Now to hear from the top 10 pharma companies on key topics including:
• The developing regulatory framework in advanced and developing markets
• The specific commercial, legal and scientific development of monoclonal antibodies
• Differentiated biosimilars: Debating their true value and potential
• Critical issues in demonstrating biosimilarity and maintaining diligent quality control
• Opportunities to drive a long term commercial strategy
• Specific Biosimilars case studies from different stakeholder perspectives
Make sure you don’t miss this fantastic opportunity
For more information and to download the brochure visit http://www.smi-online.co.uk/2011biosimilars22.asp c
About SMi Group
Biosimilars and Biobetters is just one of the many conferences that are a part of the SMi Group portfolio.
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
Zain Philbey
SMi Group
30 Great Guildford Street
SE1 0HS
+44 (0) 20 7827 6722
zphilbey@smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release What makes a Biobetter is to be discussed at SMi’s Biosimilars and Biobetters conference here
News-ID: 178401 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Biosimilars
Transformative Trends Impacting the Biosimilars Market Landscape: Innovative Pro …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Biosimilars Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The dimensions of the biosimilars market have been rapidly expanding over the last couple of years. The escalation, from a worth of $18.65 billion in 2024 to an estimated value of $21.95 billion in 2025, denotes…
Evolving Market Trends In The Biosimilars Industry: Innovative Product Launched …
The Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Biosimilars Market Size During the Forecast Period?
The dimension of the biosimilars market has experienced substantial expansion in the last few years. The market value, which was at $18.65 billion in 2024,…
Prominent Rituximab Biosimilars Market Trend for 2025: Collaborative Innovations …
Which drivers are expected to have the greatest impact on the over the rituximab biosimilars market's growth?
The rituximab biosimilars market is anticipated to grow due to the projected increase in non-Hodgkin's lymphoma (NHL) cases. NHL is a cancer that originates in the white blood cells and lymphocytes, which are integral parts of the body's immune system. For example, the American Cancer Society, a cancer advocacy group based in the US,…
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure.
According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is…
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased.
According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million…
